Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedTherapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesManaging Patients With Myelofibrosis in the Era of Janus Kinase InhibitorsMomelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.Safety considerations when treating myelofibrosis.Managing patients with myelofibrosis and low platelet counts.A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosisA phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosisNew Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Emerging drugs for the treatment of myelofibrosis.A comprehensive review of pacritinib in myelofibrosis.Myeloproliferative neoplasms: A decade of discoveries and treatment advances.Investigational Janus kinase inhibitors in development for myelofibrosis.Myelofibrosis: an update on drug therapy in 2016.Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.Interaction of 2,4-Diaminopyrimidine-Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters.Developmental Therapeutics in Myeloproliferative Neoplasms.Momelotinib therapy for myelofibrosis: a 7-year follow-up.
P2860
Q26738514-FB51C74D-D2B4-4420-B575-9D862AFAE280Q26752940-FCADE4DE-3B43-49B3-8D17-A75C6C1DD0C0Q28073296-B453672B-9461-4A25-8C16-FB824E07230DQ30244032-0DDC8E9A-2C9B-4100-B229-7AF773D2FA9AQ33422507-0FA88822-4EA9-45FE-AAFC-E0AA8DE3F78CQ33432285-F62D3F94-3466-4107-880E-3A0F3CD9D261Q33432406-C63A72BF-6C28-4CD0-ABFD-9CD5A7F3D848Q33434284-04336686-FA69-44F3-BBAD-A57D4F24483EQ33435398-A9D8438A-0C30-40F8-9063-04CFB76DC35DQ36782943-9071B6E5-13B6-4A65-A292-45FABFF4F519Q38543775-8AC7E535-F9C5-450D-BBA2-C5FB3398F6A1Q38586421-990E7CC2-E8B3-4FEA-BC16-EEC507BC38EDQ38613880-AC5CCE84-BB9B-4697-AD4A-63E7716153A3Q38691019-46FC3CB2-EDE2-448E-BC25-9D4BC2C5B284Q38989215-F90666B3-968D-413C-BF3F-08D18E37A13CQ39015300-ED4B7FBD-90CF-43BD-BE83-CD0739034425Q46032293-7DE5CEA6-543F-47BD-B475-EC0FDDD855BAQ48008083-2A2E83A2-70F0-4F11-823D-A364D02DF417Q54998956-92C3F58B-14FF-41B6-AD1E-05615A4F4F3A
P2860
Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Momelotinib treatment-emergent ...... 0 patients with myelofibrosis.
@en
Momelotinib treatment-emergent ...... 0 patients with myelofibrosis.
@nl
type
label
Momelotinib treatment-emergent ...... 0 patients with myelofibrosis.
@en
Momelotinib treatment-emergent ...... 0 patients with myelofibrosis.
@nl
prefLabel
Momelotinib treatment-emergent ...... 0 patients with myelofibrosis.
@en
Momelotinib treatment-emergent ...... 0 patients with myelofibrosis.
@nl
P2093
P2860
P356
P1476
Momelotinib treatment-emergent ...... 0 patients with myelofibrosis.
@en
P2093
Animesh Pardanani
Aref Al-Kali
Kebede H Begna
Mark R Litzow
Ramy A Abdelrahman
William J Hogan
P2860
P356
10.1111/BJH.13262
P407
P577
2014-12-15T00:00:00Z